Company intelligence / Profile preview
Guangzhou Doublle Bioproduct Co., Ltd.
Guangzhou, Guangdong Province, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Initial results from the Phase III study of Adenolysin show encouraging efficacy signals with potential significant benefit to patients with head & neck cancers. Additional programs have reached IND clearance or early phase trials.
- Therapeutic areas
- GastroenterologyOncologyNephrology
- Modalities
- Gene therapyCell therapyMonoclonal antibodyCAR-NK cell therapiesCAR-T cell therapies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Guangzhou Doublle Bioproduct Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Doublle Bioproduct Co., Ltd..